Published in Clin Cancer Res on August 15, 2004
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle (2015) 1.41
Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis. PLoS One (2012) 0.99
Polymorphisms in the ERCC5 gene and risk of esophageal squamous cell carcinoma (ESCC) in Eastern Chinese populations. PLoS One (2012) 0.97
Association study between XPG Asp1104His polymorphism and colorectal cancer risk in a Chinese population. Sci Rep (2014) 0.93
Nucleotide excision repair in humans. DNA Repair (Amst) (2015) 0.93
Cis-acting genetic variation at an E2F1/YY1 response site and putative p53 site is associated with altered allele-specific expression of ERCC5 (XPG) transcript in normal human bronchial epithelium. Carcinogenesis (2010) 0.91
The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma. Pak J Med Sci (2013) 0.85
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil. Invest New Drugs (2008) 0.82
ERCC6L2 mutations link a distinct bone-marrow-failure syndrome to DNA repair and mitochondrial function. Am J Hum Genet (2014) 0.82
Polymorphisms of XPG/ERCC5 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics (2012) 0.81
Transcription-coupled repair: an update. Arch Toxicol (2016) 0.81
Susceptibility of the antioxidant selenoenyzmes thioredoxin reductase and glutathione peroxidase to alkylation-mediated inhibition by anticancer acylfulvenes. Chem Res Toxicol (2011) 0.80
XPG Gene Polymorphisms Contribute to Colorectal Cancer Susceptibility: A Two-Stage Case-Control Study. J Cancer (2016) 0.79
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Chem Res Toxicol (2016) 0.77
Profiling patterns of glutathione reductase inhibition by the natural product illudin S and its acylfulvene analogues. Mol Biosyst (2009) 0.77
Improved efficacy of acylfulvene in colon cancer cells when combined with a nuclear excision repair inhibitor. Chem Res Toxicol (2013) 0.76
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget (2016) 0.76
Current evidences on the XPG Asp1104His polymorphism and melanoma susceptibility: a meta-analysis based on case-control studies. Mol Genet Genomics (2014) 0.76
Functional Analysis of SNPs in the ERCC5 Promoter in Advanced Colorectal Cancer Patients Treated With Oxaliplatin-Based Chemotherapy. Medicine (Baltimore) (2016) 0.75
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2005) 7.12
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol (2009) 4.27
Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov (2007) 4.27
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res (2005) 3.44
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol (2009) 2.53
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol (2013) 2.46
UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell (2003) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Survey of human genes of retroviral origin: identification and transcriptome of the genes with coding capacity for complete envelope proteins. J Virol (2003) 2.31
miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res (2010) 2.24
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Involvement of p38alpha in the mitotic progression of p53(-/-) tetraploid cells. Cell Cycle (2010) 2.08
TP53 mutations in human skin cancers. Hum Mutat (2003) 2.07
Incidence of DNA repair deficiency disorders in western Europe: Xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. DNA Repair (Amst) (2008) 2.02
Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol (2008) 2.01
FOXO1 regulates L-Selectin and a network of human T cell homing molecules downstream of phosphatidylinositol 3-kinase. J Immunol (2008) 1.97
Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One (2012) 1.93
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc Chem Res (2003) 1.88
The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat Res (2005) 1.86
The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes. Blood (2006) 1.81
Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol (2005) 1.80
Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther (2007) 1.74
Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol (2007) 1.73
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol (2013) 1.71
How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull (2009) 1.69
Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol (2009) 1.68
New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol (2006) 1.67
ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis (2002) 1.65
Molecular analysis of mutations in DNA polymerase eta in xeroderma pigmentosum-variant patients. Proc Natl Acad Sci U S A (2002) 1.63
A prevalent mutation with founder effect in xeroderma pigmentosum group C from north Africa. J Invest Dermatol (2010) 1.61
DNA polymerase eta is involved in hypermutation occurring during immunoglobulin class switch recombination. J Exp Med (2004) 1.59
DNA repair: from molecular mechanism to human disease. DNA Repair (Amst) (2006) 1.56
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res (2003) 1.55
Role of DNA polymerase eta in the UV mutation spectrum in human cells. J Biol Chem (2003) 1.53
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res (2011) 1.52
XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha. Cell (2002) 1.51
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A (2007) 1.43
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder. Cell Cycle (2015) 1.41
ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol (2005) 1.41
Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. DNA Repair (Amst) (2008) 1.40
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res (2011) 1.39
DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2004) 1.37
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer (2012) 1.31
What histone code for DNA repair? Mutat Res (2008) 1.31
Human DNA polymerase iota protects cells against oxidative stress. EMBO J (2008) 1.31
Reduced XPC DNA repair gene mRNA levels in clinically normal parents of xeroderma pigmentosum patients. Carcinogenesis (2005) 1.30
Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. Carcinogenesis (2007) 1.27
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet (2007) 1.27
Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev (2013) 1.26
A UV-sensitive syndrome patient with a specific CSA mutation reveals separable roles for CSA in response to UV and oxidative DNA damage. Proc Natl Acad Sci U S A (2009) 1.26
A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res (2007) 1.26
Network enrichment analysis: extension of gene-set enrichment analysis to gene networks. BMC Bioinformatics (2012) 1.24
Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway. PLoS One (2007) 1.23
Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood (2006) 1.21
Epigenetic regulation of an IAP retrotransposon in the aging mouse: progressive demethylation and de-silencing of the element by its repetitive induction. Nucleic Acids Res (2002) 1.19
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res (2009) 1.18
The DNA repair genes XPB and XPD defend cells from retroviral infection. Proc Natl Acad Sci U S A (2006) 1.18
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. Invest New Drugs (2007) 1.18
Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev (2013) 1.18
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol (2007) 1.16
Ocular manifestations in the inherited DNA repair disorders. Surv Ophthalmol (2003) 1.16
NF-kappaB and p53 are the dominant apoptosis-inducing transcription factors elicited by the HIV-1 envelope. J Exp Med (2004) 1.13
Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res (2009) 1.12
Targeted agents for adjuvant therapy of colon cancer. Semin Oncol (2006) 1.12
Deletion of 5' sequences of the CSB gene provides insight into the pathophysiology of Cockayne syndrome. Eur J Hum Genet (2008) 1.12
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer (2010) 1.09
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer. Expert Opin Investig Drugs (2010) 1.09
Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol (2005) 1.09
Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas. Oncotarget (2014) 1.08
Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev (2013) 1.08
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res (2011) 1.08
Transcription through 8-oxoguanine in DNA repair-proficient and Csb(-)/Ogg1(-) DNA repair-deficient mouse embryonic fibroblasts is dependent upon promoter strength and sequence context. Mutagenesis (2007) 1.08
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag (2007) 1.07
Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol (2005) 1.07
Global genome repair is required to activate KIN17, a UVC-responsive gene involved in DNA replication. Proc Natl Acad Sci U S A (2003) 1.07
Independent transcriptional reprogramming and apoptosis induction by cisplatin. Cell Cycle (2012) 1.07
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol (2011) 1.07
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer (2005) 1.05
Adjuvant therapy for stage II and III colorectal cancer. Semin Oncol (2007) 1.05
Hypothetical role of RNA damage avoidance in preventing human disease. Mutat Res (2005) 1.05
Lung cancer and DNA repair genes: multilevel association analysis from the International Lung Cancer Consortium. Carcinogenesis (2012) 1.05
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist (2011) 1.05
PARPs and the DNA damage response. Carcinogenesis (2012) 1.05
Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression. Virchows Arch (2012) 1.05
Infantile convulsions with paroxysmal dyskinesia (ICCA syndrome) and copy number variation at human chromosome 16p11. PLoS One (2010) 1.04